Paget’s disease, a chronic bone disorder characterized by abnormal bone remodeling, affects millions worldwide and presents significant treatment challenges. The paget's disease treatment market has seen growth driven by an aging population, increasing awareness, and advancements in treatment options. Bisphosphonates, such as zoledronic acid and alendronate, are the primary therapies, effectively managing symptoms and slowing disease progression. Recent developments include emerging treatments focusing on novel drug mechanisms and improved patient adherence strategies. Additionally, ongoing research into genetic and environmental factors influencing Paget's disease may lead to more personalized treatment approaches. With a growing emphasis on holistic care and patient outcomes, the market is poised for expansion, addressing both current and unmet medical needs in paget’s disease management.
